Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection

Journal of Viral Hepatitis

Volumn 22, Issue 12, 2015, Pages 974-976

  Sethi, N ^a   Tapper, E B ^a   Vong, A ^a   Sethi, S ^a   Rourke, M ^a   Afdhal, N H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

boceprevir; cost effectiveness; direct acting antivirals; interferon; telaprevir

Indexed keywords

ANTIANEMIC AGENT; ANTIVIRUS AGENT; FILGRASTIM; RECOMBINANT INTERFERON; RIBAVIRIN; ALPHA INTERFERON; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; TELAPREVIR;

ADULT; ARTICLE; CHRONIC HEPATITIS C; DRUG COST; DRUG INDICATION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HEPATITIS C VIRUS GENOTYPE 1; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; TERTIARY CARE CENTER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; GENETICS; HEALTH CARE COST; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN; TERTIARY CARE CENTERS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84945444376     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12421     Document Type: Article

References (9)

1. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370 (20): 1889-1898.
2. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1207-1217.
3. Hoofnagle JH, Sherker AH,. Therapy for hepatitis C-the costs of success. N Engl J Med 2014; 370 (16): 1552-1553.
4. Bichoupan K, Martel-Laferriere V, Sachs D, et al,. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology 2014; 60 (4): 1187-1195.
5. HCUPnet. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville, MD, USA: HHCaUP, 2011.
6. Thomson Reuters (Healthcare) Inc. Red Book Online. Greenwood Village, CO: Truven Health Analytics, Inc: Thomson Reuters (Healthcare) Inc, 2013.
7. Bruno S, Bollani S, Zignego AL, et al,. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. J Viral Hepatitis 2015; 22 (5): 469-480.
8. Saab S, Gordon S, Park H, Sulkowski M, Ahmed A, Younossi Z,. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014; 40 (6): 657-675.
9. Hagan L, Yang Z, Ehteshami M, Schinazi R,. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepatitis 2013; 20 (12): 847-857.